Skip to main navigation

Skip to Content

Stock
Financials
- SEC Filings
- Financial Reports
News & Events
Corporate Governance
Our Company
IR Resources

Press Releases

Year

Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme

May 04, 2022

Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma

May 02, 2022

Genenta Announces Nomination of Mark A. Sirgo as Chair

Apr 27, 2022

Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors

Apr 20, 2022

Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme

Mar 09, 2022

Genenta to Participate at Upcoming Investor Conferences

Feb 24, 2022

Genenta Closes Its Upsized Initial Public Offering of American Depository Shares

Dec 17, 2021

Genenta Announces Pricing of Upsized Initial Public Offering

Dec 14, 2021

Genenta to present updated Phase I/II data at upcoming scientific congresses SNO and ASH

Nov 16, 2021

Genenta announces filing of registration statement for proposed initial public offering

Nov 10, 2021

Pagination

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Page 5
Page 6
Next page
Last page

Displaying 21 - 30 of 59

Investor Contact

RSS Feeds

Print

ITALY
Dibit – San Raffaele Hospital
Via Olgettina, 58
20132 Milano

UNITED STATES
LaunchLabs – Alexandria Center
430 East 29th Street
New York NY 10016

PARTNERS

genenta-img-san_raffaele

© 2024 Genenta Science. All rights reserved - - Terms and conditions - Privacy Policy